Elsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process.
The tool enables researchers to track predictions through the development cycle from pre-clinical to phase III trials and project manage multiple simulations at the same time. It also assists with inclusion and exclusion criteria for patients in phase II and III trials.
For more information, click
